AP1189 is used for the treatment of early rheumatoid arthritis patients with severe disease activity. Credit: David Richfield / commons.wikimedia.org.

SynAct Pharma has completed enrolling patients in a Phase IIb EXPAND clinical trial of AP1189 for the treatment of early rheumatoid arthritis (RA) patients with severe disease activity.

The EXPAND is a continuation of BEGIN study, which demonstrated a fast and clinical meaningful reduction in the patient’s disease activity using AP1189 against placebo treatment following four weeks of treatment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Previously treated naive patients with severe RA will receive AP1189 in combination with first-line treatment Methotrexate in the multicentre, randomised, double-blind, placebo-controlled EXPAND study.

Being designed as a once daily dosage form, AP1189 tablet formulation will be dosed for 12 weeks to a total of 127 randomised patients.

SynAct Pharma CSO Thomas Jonassen said: “It’s satisfying to announce that the last patient in the EXPAND study was enroled well ahead of schedule.

“We now look forward to completing the dosing and reporting the study,” Jonassen added.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dosing of the patients with AP1189 is expected to be completed in this July, while the last patient’s safety follow-up visit will be carried out in August.

The company is planning to announce the top-line study data in approximately five months.

AP1189, which reduces inflammation, is said to circumvent the safety issues related to suppression of the immune system against other therapies.